Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont
about
Certolizumab pegol (CDP870) for rheumatoid arthritis in adultsCertolizumab pegol (CDP870) for rheumatoid arthritis in adultsCertolizumab pegolBiologic interventions for fatigue in rheumatoid arthritisComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyHealth-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison.Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegolLong-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialCertolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trialCost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain.Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysisCellular and humoral mechanisms involved in the control of tuberculosisLong-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID studyTofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisSarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.Certolizumab pegol: a new biologic targeting rheumatoid arthritis.The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis.RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis.Indirect comparison of biological treatments in refractory rheumatoid arthritis.Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers.Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.The efficacy of motivational counselling and SMS reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial.Guidelines for the drug treatment of rheumatoid arthritis.Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritisTreatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland
P2860
Q24193535-9ED02622-C98E-4052-A58B-762F9F00E224Q24236701-C76CE462-2E0C-4A67-9981-1F6EFFF04EBDQ24625401-3D3F99F4-747C-4178-93BD-9F00E822CBE5Q26471538-16586E42-6028-47A6-9044-8D713A9B9AEAQ27694496-A095C1FE-F346-4C53-86E3-089D2C99331BQ30957102-1323E83F-0773-49D8-9A22-8B1BA9936C85Q33591510-B4EF87FF-CAB8-46C2-AF7E-27ECA5F48417Q33690668-481C3D35-BD47-4078-A9B0-ED5DC5E39552Q34117111-FAF62B93-7040-482F-9D51-8DAD5FF08B71Q34607794-9F3A05D6-F907-4061-9D1D-E7E9C0ECCF01Q34769757-7C0CA364-5BFE-41BE-93F0-CCD439827AC4Q34905646-8D1312D5-32ED-49CC-A79F-803EC97E9B02Q35351313-3EBD725D-5373-48D3-A464-A037158B9DF3Q35795354-2623FD03-471D-4B65-8E11-FD7175C8EEB6Q35907809-AEC699EB-97A5-4490-BC7D-27DA209ED98BQ35996521-5EF60194-CA24-4FF3-BD9D-3F8F7D26D992Q36761836-D6148241-7FC7-4E4F-A1D6-77F734CA32FFQ36910016-3343D0E5-2BF9-402D-B746-FA171EA71966Q37233468-BB1482A4-748E-4966-B525-C153AEF35731Q37587412-85F583F5-4716-4F2A-ABB5-504518F05673Q37676988-E4AE29BC-D739-45A0-8CB1-5FF5F3C72285Q37709364-00C5DD1B-8B60-49F7-9B18-6F3126123F4FQ37786625-4B88C332-F08E-4E65-8769-FE9CDE47B42DQ37868377-F22D1AE6-13FC-4E1D-AE43-E59F0C552441Q37914956-A2FC16E6-AE32-4E43-867B-F9A5B291458DQ37928726-ABD5E91A-7E0F-43A9-B077-93FD786225FCQ38075801-D18BA50E-9C2C-4AB2-B2C4-D50F23E508E7Q38200927-D2756AB7-F426-45C3-B3B3-4EB0725BBC23Q38939820-9FBC6E09-CCAA-4734-A3E9-56BBA6C9054EQ38972531-C3E2B779-7F3E-447E-AB01-0BF14C144122Q41028325-7793CD62-9712-4BD1-9C3B-677A66572FFEQ41449471-796EC5DE-3F10-4E3C-AC42-1904EADC16A2Q43675571-77114DE5-5286-46B8-8F0D-52067097C9FCQ44818742-E15BBC88-213F-4EAC-B703-EE5B3E931092Q46030948-B6F4F990-1E2C-4926-8291-2ACC72CF2713Q47836056-D9FF784C-36D8-4266-A8E4-D8E620C11CAFQ57330038-8CD10009-3D1C-49F1-A88D-390E0D0D4D7BQ58800873-A354918C-6A9B-4C82-8FA0-3E235AA9E8C4
P2860
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@ast
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@en
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@nl
type
label
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@ast
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@en
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@nl
prefLabel
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@ast
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@en
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@nl
P2093
P2860
P356
P1476
Rapid and sustained improvemen ...... om the RAPID 1 randomized cont
@en
P2093
Arthur Kavanaugh
Bernard Combe
Edward C Keystone
Enkeleida Nikaï
Geoffroy Coteur
Philip Mease
Vibeke Strand
P2860
P2888
P356
10.1186/AR2859
P577
2009-11-12T00:00:00Z
P5875
P6179
1041294353